| 0.6195 -0.031 (-4.72%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.86 | 1-year : | 1.02 |
| Resists | First : | 0.74 | Second : | 0.87 |
| Pivot price | 0.74  |
|||
| Supports | First : | 0.51 | Second : | 0.43 |
| MAs | MA(5) : | 0.69 |
MA(20) : | 0.7 |
| MA(100) : | 1.22 |
MA(250) : | 3.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 34.4 |
D(3) : | 45.6 |
| RSI | RSI(14): 38.9 |
|||
| 52-week | High : | 6.42 | Low : | 0.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BCTX ] has closed above bottom band by 1.3%. Bollinger Bands are 53.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.67 - 0.67 | 0.67 - 0.68 |
| Low: | 0.6 - 0.61 | 0.61 - 0.61 |
| Close: | 0.61 - 0.62 | 0.62 - 0.63 |
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Tue, 10 Sep 2024
BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer - StockTitan
Mon, 09 Sep 2024
BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - StockTitan
Sun, 08 Sep 2024
BriaCell shares rise on strong data from breast cancer treatment study - MSN
Thu, 18 Jul 2024
BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer - GlobeNewswire
Tue, 28 May 2024
BriaCell Therapeutics (BCTX) Enters Clinical Supply Agreement with BeiGene (BGNE) for Bria-OTS - StreetInsider.com
Fri, 17 May 2024
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 18 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 15.5 (%) |
| Held by Institutions | 10.9 (%) |
| Shares Short | 417 (K) |
| Shares Short P.Month | 569 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -122.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -1.68 |
| PEG Ratio | 0 |
| Price to Book value | -1.68 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|